Shah, Nisarg J. http://orcid.org/0000-0003-1727-5732
Najibi, Alexander J. http://orcid.org/0000-0001-7761-392X
Shih, Ting-Yu
Mao, Angelo S.
Sharda, Azeem
Scadden, David T. http://orcid.org/0000-0001-9821-7133
Mooney, David J. http://orcid.org/0000-0001-6299-1194
Funding for this research was provided by:
Cancer Research Institute
National Science Foundation
U.S. Department of Health & Human Services | National Institutes of Health (U19HL129903, R01CA223255, R01EB023287, U01CA214369)
Article History
Received: 18 September 2018
Accepted: 3 December 2019
First Online: 14 January 2020
Competing interests
: Magenta Therapeutics, director, equity and consulting: D.T.S.; Agios Pharmaceuticals, director, equity: D.T.S.; Fate Therapeutics, equity and consulting: D.T.S.; Clear Creek Bio, director, equity and consulting: D.T.S.; FOG Pharma, consulting: D.T.S.; Red Oak Medicines, director, equity and consulting: D.T.S.; Lifevaultbio, director, equity: D.T.S.; Bone Therapeutics, consulting: D.T.S.; Indee Labs, consulting: A.J.N.; Novartis, sponsored research: D.T.S and D.J.M.; Agnovos, consulting: D.J.M.; Amgen, sponsored research: D.J.M.; Samyang Corp., consulting: D.J.M.; Decibel, sponsored research: D.J.M.; Merck, sponsored research: D.J.M.; Immulus, equity: D.J.M.; Inventors, patent applications: N.J.S., A.J.N., A.S.M., T.-Y.S., D.J.M. and D.T.S.